Tidal Investments LLC Sells 28,619 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Tidal Investments LLC lowered its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 67.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,856 shares of the company’s stock after selling 28,619 shares during the period. Tidal Investments LLC’s holdings in Teva Pharmaceutical Industries were worth $250,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB bought a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $50,000. Sanctuary Advisors LLC boosted its holdings in Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock valued at $601,000 after acquiring an additional 664 shares during the period. TCW Group Inc. bought a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,286,000. Geode Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after purchasing an additional 291,124 shares during the period. Finally, Barclays PLC lifted its position in Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company’s stock valued at $7,705,000 after purchasing an additional 102,848 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent analyst reports. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. UBS Group raised their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, Barclays lifted their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.88.

Teva Pharmaceutical Industries Trading Up 0.9 %

Shares of NYSE TEVA opened at $22.42 on Thursday. The firm’s 50 day moving average price is $17.97 and its 200-day moving average price is $17.60. Teva Pharmaceutical Industries Limited has a 52-week low of $10.34 and a 52-week high of $22.50. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a market cap of $25.40 billion, a PE ratio of -26.38, a P/E/G ratio of 0.99 and a beta of 0.79.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.